Medical Device CDMOs Market Size, Share, By Service Type (Device Development, Testing & Validation, Quality Management, Packaging & Labeling, Regulatory Services, and Others), Device Type (Therapeutic Medical Devices, Diagnostic Medical Devices, Drug Delivery Medical Devices, and Others), Device Class (Class I, Class II, Class III, and Others), Indication (Oncology, Orthopedic, Neurology, Cardiology, and Others), End User (Startups Companies, Mid-size Companies, and Large Medical Device Companies), and Region - Trends, Analysis, and Forecast till 2035

TE Connectivity, Gerresheimer AG, Viant, FLEX LTD, Integer Holdings Corporation, and other major competitors are involved in the Medical Device CDMOs market. Key strategies for medical device CDMOs include investing in advanced manufacturing technologies (like automation and 3D printing), expanding service offerings to provide end-to-end solutions, forming strategic partnerships with OEMs and startups, adhering strictly to regulations, and focusing on innovation to support complex, high-value devices. Resilient supply chains and international expansion are also necessary to remain competitive in a market that is changing rapidly.

List of Key Players in the Market:

• TE Connectivity
• Gerresheimer AG
• SANNER
•  Phillips Medisize – a Molex Company
•  FLEX LTD
•  Integer Holdings Corporation
• Sfm medical devices GmbH
• NIPRO CORPORATION
• Viant
•  SteriPack Group
• Tegra Medical
• Cadence, Inc.
• Resonetics
• Salt Medical
• Nordson MEDICAL

Recent News:

• PCI Pharma Services, a leading global contract development and manufacturing organization (CDMO) that specializes in innovative biopharma medications, on April 20205, acquired a full ownership stake in Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. The acquisition, which is anticipated to be finalized in May 2025, provides PCI with its first-ever prefilled syringe and cartridge manufacturing facility in North America, complete with isolator technology for these formats, as well as high-potency manufacturing facilities suitable for antibody-drug conjugates (ADCs).
• According to Raichur-centered Shilpa Medicare has created a new full-service "hybrid" contract development and manufacturing organization (or CDMO). At the recently created CDMO, Shilpa will help clients with peptides, small and large molecules, and oncology as a specific therapeutic focus. Additionally, Shilpa's "hybrid CDMO model" includes economically viable "off-the-shelf" novel formulations for exclusive business-to-business licenses in addition to offering comprehensive clinical, commercial, and discovery outsourcing services.